Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: S. Kumar Examiner #: 69594 Date: 8/31/06
Art Unit: 1621 Phone Number: 2-0640 Serial Number: 10/580,902
Location (Bldg/Room#): RFM (Mailbox #): 5C18 Results Format Preferred (circle): PAPER DISK
5C03

****

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: Novel Compounds

Inventors (please provide full names): Neeraj Garg et al.

Earliest Priority Date: 7/10/02

1. (Original) N-[3,5-Dichloro-4-(4-hydroxy-3-isopropyl-5-methylphenoxy)benzoyl] glycine (E1);

N-[3,5-Dichloro-4-(3-bromo-4-hydroxy-5-isopropylphenoxy)benzoyl] glycine (E2);

N-[3,5-Dichloro-4-(2-bromo-4-hydroxy-5-isopropylphenoxy)benzoyl] glycine (E3);

N-[3,5-Dichloro-4-(3-chloro-4-hydroxy-5-isopropylphenoxy)benzoyl] glycine (E4);

N-[3,5-Dichloro-4-(3-cyano-4-hydroxy-5-isopropylphenoxy)benzoyl] glycine (E5);

N-[3,5-Dichloro-4-(3-fluoro-4-hydroxy-5-isopropylphenoxy)benzoyl] glycine (E6)

N-[3,5-Dichloro-2-methyl-4-(3-methyl-4-hydroxy-5-isopropylphenoxy)benzoyl] glycine (E7)

L-N-[3,5-Dibromo-4-(3-fluoro-4-hydroxy-5-isopropylphenoxy)phenylacetyl] valine (E10)

D-N-[3,5-Dibromo-4-(3-chloro-4-hydroxy-5-isopropylphenoxy)phenylacetyl] phenylglycine (E11)

L-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropyl-5-methylphenoxy)phenylacetyl] valine (E12)

L-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropyl-5-methylphenoxy)phenylacetyl]phenylglycine (E13)

L-N-[3,5-Dibromo-4-(3,5-dimethyl-4-hydroxyphenoxy)phenylacetyl]-phenylglycine (E14)

N-[3,5-Dibromo-2-methyl-4-(3-methyl-4-hydroxy-5-isopropylphenoxy)benzoyl] glycine (E8)

N-[3,5-Dimethyl-2-methyl-4-(3-methyl-4-hydroxy-5-isopropylphenoxy)benzoyl] glycine (E9).

2. (Canceled)

3. (Original) A pharmaceutical composition comprising an effective amount of a compound according to claim 1 or a pharmaceutically effective salt thereof, together with a pharmaceutically acceptable carrier.

4. (Original) A process for making a pharmaceutical composition comprising combining a compound according to

THIS PAGE LEFT BLANK

```
=> d que stat l11
L1                  STR
```



```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  26

STEREO ATTRIBUTES: NONE
L3              44 SEA FILE=REGISTRY SSS FUL L1
L4                  STR
```



```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  24

STEREO ATTRIBUTES: NONE
L6               3 SEA FILE=REGISTRY SSS FUL L4
L7              44 SEA FILE=REGISTRY ABB=ON  L3 OR L6
L8               3 SEA FILE=HCAPLUS ABB=ON  L7
L9               2 SEA FILE=HCAPLUS ABB=ON  L8 AND (PRD<20020710 OR PD<20020710)
L10              3 SEA FILE=USPATFULL ABB=ON  L8 AND (PRD<20020710 OR PD<20020710)
L11              5 DUP REMOV L9 L10 (0 DUPLICATES REMOVED)

=> d ibib abs hitstr l11 1-5

L11  ANSWER 1 OF 5  USPATFULL on STN
ACCESSION NUMBER:       2006:17927  USPATFULL
```

TITLE: Thyroid receptor ligands and method II
INVENTOR(S): Hangeland, Jon, Morrisville, PA, UNITED STATES
Zhang, Minsheng, Warren, NJ, UNITED STATES
Caringal, Yolanda, Lawrenceville, NJ, UNITED STATES
Ryono, Denis, Princeton, NJ, UNITED STATES
Li, Yi-Lin, Huddinge, SWEDEN
Malm, Johan, Skogas, SWEDEN
Liu, Ye, Tullinge, SWEDEN
Garg, Neeraj, Tumba, SWEDEN
Litten, Chris, Tumba, SWEDEN
Collazo, Ana Maria Garcia, Stockholm, SWEDEN
Koehler, Konrad, Huddinge, SWEDEN
PATENT ASSIGNEE(S): Karo Bio AB, Huddinge, SWEDEN (non-U.S. corporation)

	NUMBER	KIND	DATE		
PATENT INFORMATION:	US 6989402	B1	20060124		
	WO 2000039077		20000706		<--
APPLICATION INFO.:	US 2001-868889		19991223	(9)	
	WO 1999-IB2084		19991223		
			20010914	PCT 371 date	

	NUMBER	DATE	
PRIORITY INFORMATION:	GB 1998-28442	19981224	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: McKane, Joseph K.
ASSISTANT EXAMINER: Coppins, Janet L.
LEGAL REPRESENTATIVE: Garabedian, Todd E., Wiggin and Dana LLP
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 1966
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; R.sub.1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R.sub.2 and R.sub.3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, at least one of R.sub.2 and R.sub.3 being other than hydrogen; R.sub.4 is a carboxylic acid amide (CONR'R") or an acylsulphonamide (CONHSO2R') derivative, or a pharmaceutically acceptable salt thereof, and all stereoisomers thereof; or when n is equal to or greater than one, R.sub.4 may be a heteroaromatic moiety which may be substituted or unsubstituted, or an amine (NR'R"). R.sub.5 is hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (wherein R.sub.5=H). In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T.sub.3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T.sub.3 regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **280777-33-5P 280777-34-6P 280777-35-7P**
280777-36-8P 280777-37-9P 280777-38-0P

280777-39-1P 280777-40-4P 280777-42-6P
280777-43-7P 280777-44-8P 280777-45-9P
280777-46-0P 280777-47-1P 280777-48-2P
280777-50-6P 280777-51-7P 280777-52-8P
280777-53-9P 280777-54-0P 280777-55-1P
280777-56-2P 280777-57-3P 280777-58-4P
280777-88-0P 280779-25-1P 280779-31-9P
280779-32-0P
(preparation of (hydroxyphenoxy)phenylacetyl amino acids and related compds. as novel thyroid receptor ligands)

RN 280777-33-5 USPATFULL
CN D-Valine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-34-6 USPATFULL
CN D-Leucine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-35-7 USPATFULL
CN L-Cysteine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- S-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-36-8 USPATFULL
CN D-Tyrosine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-37-9 USPATFULL
CN L-Ornithine, N2-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 280777-38-0 USPATFULL
CN Butanoic acid, 2-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-39-1 USPATFULL
CN L-Valine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-40-4 USPATFULL
CN L-Leucine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-42-6 USPATFULL
CN L-Cysteine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-43-7 USPATFULL
CN Glycine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-
(9CI) (CA INDEX NAME)



RN 280777-44-8 USPATFULL
CN L-Lysine, N2-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-45-9 USPATFULL
CN D-Lysine, N2-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-46-0 USPATFULL
CN Alanine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 280777-47-1 USPATFULL
CN Benzeneacetic acid, α-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-48-2 USPATFULL
CN Benzeneacetic acid, α-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]amino]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-50-6 USPATFULL
CN Phenylalanine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-α-methyl- (9CI) (CA INDEX NAME)



RN 280777-51-7 USPATFULL
CN L-Isoleucine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-52-8 USPATFULL
CN D-Methionine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-53-9 USPATFULL
CN L-Methionine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-54-0 USPATFULL
CN L-Phenylalanine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-55-1 USPATFULL
CN D-Phenylalanine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-56-2 USPATFULL
CN Cyclohexanepropanoic acid, α-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-57-3 USPATFULL
CN L-Lysine, N2-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-N6-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-58-4 USPATFULL
CN D-Lysine, N2-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-N6-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-88-0 USPATFULL
CN Glycine, N-[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 280779-25-1 USPATFULL
CN D-Methionine, N-[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280779-31-9 USPATFULL
CN L-Serine, N-[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280779-32-0 USPATFULL
CN D-Serine, N-[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 2 OF 5 USPATFULL on STN
ACCESSION NUMBER: 2005:324960 USPATFULL
TITLE: Novel thyroid receptor ligands and method II
INVENTOR(S): Hangeland, Jon, Morrisville, PA, UNITED STATES
Zhang, Minsheng, Warren, NJ, UNITED STATES
Caringal, Yolanda, Lawrenceville, NJ, UNITED STATES
Ryono, Denis, Princeton, NJ, UNITED STATES
Li, Yi-Lin, Huddinge, SWEDEN
Malm, Johan, Skogas, SWEDEN
Liu, Ye, Tullinge, SWEDEN
Garg, Neeraj, Tumba, SWEDEN
Litten, Chris, Tumba, SWEDEN
Collazo, Ana Maria Garcia, Stockholm, SWEDEN
Koehler, Konrad, Huddinge, SWEDEN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005282872	A1	20051222
APPLICATION INFO.:	US 2005-189654	A1	20050726 (11)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-868889, filed on 14 Sep 2001, PENDING A 371 of International Ser. No. WO 1999-IB2084, filed on 23 Dec 1999

	NUMBER	DATE	
PRIORITY INFORMATION:	GB 1998-28442	19981224	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WIGGIN AND DANA LLP, ATTENTION: PATENT DOCKETING, ONE CENTURY TOWER, P.O. BOX 1832, NEW HAVEN, CT, 06508-1832, US
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
LINE COUNT: 2022
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; R.sub.1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R.sub.2 and R.sub.3 are the same or differential hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, at least one of R.sub.2 and R.sub.3 being other than hydrogen; R.sub.4 is a carboxylic acid thereof; or when n is equal to or greater than one, R.sub.4 may be heteroaromatic moiety which may be substituted or unsubstituted, or an amine (NR'R"). R.sub.5 is hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (wherein R.sub.5--H). In addition, a method is provided for preventing, inhibiting or treating a disease

associated with metabolism dysfunction or which is dependant upon the expression of a T.sub.3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T.sub.3 regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **280777-33-5P 280777-34-6P 280777-35-7P**
280777-36-8P 280777-37-9P 280777-38-0P
280777-39-1P 280777-40-4P 280777-42-6P
280777-43-7P 280777-44-8P 280777-45-9P
280777-46-0P 280777-47-1P 280777-48-2P
280777-50-6P 280777-51-7P 280777-52-8P
280777-53-9P 280777-54-0P 280777-55-1P
280777-56-2P 280777-57-3P 280777-58-4P
280777-88-0P 280779-25-1P 280779-31-9P
280779-32-0P
(preparation of (hydroxyphenoxy)phenylacetyl amino acids and related compds. as novel thyroid receptor ligands)

RN 280777-33-5 USPATFULL

CN D-Valine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-34-6 USPATFULL

CN D-Leucine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-35-7 USPATFULL

CN L-Cysteine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- S-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-36-8 USPATFULL
CN D-Tyrosine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-37-9 USPATFULL
CN L-Ornithine, N2-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 280777-38-0 USPATFULL
CN Butanoic acid, 2-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-39-1 USPATFULL
CN L-Valine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-40-4 USPATFULL
CN L-Leucine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-42-6 USPATFULL
CN L-Cysteine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-43-7 USPATFULL
CN Glycine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-
(9CI) (CA INDEX NAME)



RN 280777-44-8 USPATFULL
CN L-Lysine, N2-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-45-9 USPATFULL
CN D-Lysine, N2-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-46-0 USPATFULL
CN Alanine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-2-
methyl- (9CI) (CA INDEX NAME)



RN 280777-47-1 USPATFULL
CN Benzeneacetic acid, α-[[3,5-dibromo-4-[4-hydroxy-3-(1-
methylethyl)phenoxy]benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-48-2 USPATFULL
CN Benzeneacetic acid, α-[[3,5-dibromo-4-[4-hydroxy-3-(1-
methylethyl)phenoxy]benzoyl]amino]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-50-6 USPATFULL
CN Phenylalanine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-α-methyl- (9CI) (CA INDEX NAME)



RN 280777-51-7 USPATFULL
CN L-Isoleucine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-52-8 USPATFULL
CN D-Methionine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-53-9 USPATFULL
CN L-Methionine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-54-0 USPATFULL
CN L-Phenylalanine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-55-1 USPATFULL
CN D-Phenylalanine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-56-2 USPATFULL
CN Cyclohexanepropanoic acid, α-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-57-3 USPATFULL
CN L-Lysine, N2-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-N6-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-58-4 USPATFULL
CN D-Lysine, N2-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-N6-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-88-0 USPATFULL
CN Glycine, N-[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 280779-25-1 USPATFULL
CN D-Methionine, N-[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280779-31-9 USPATFULL
CN L-Serine, N-[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280779-32-0 USPATFULL
CN D-Serine, N-[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 3 OF 5 USPATFULL on STN

ACCESSION NUMBER:	2002:122675 USPATFULL		
TITLE:	Benzamide ligands for the thyroid receptor		
INVENTOR(S):	Ryono, Denis E., Princeton, NJ, United States		
PATENT ASSIGNEE(S):	Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6395784	B1	20020528 <--
APPLICATION INFO.:	US 2001-871347		20010531 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 2000-210102P		20000607 (60) <--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Killos, Paul J.		
LEGAL REPRESENTATIVE:	Kilcoyne, John M.		
NUMBER OF CLAIMS:	29		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	982		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB New thyroid receptor ligands are provided which have the general formula ##STR1##

in which:

X is --O--, --S--, --CH.sub.2--, --CO--, or --NH--;

R.sub.1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons;

R.sub.2 and R.sub.3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 6 carbons, at least one of R.sub.2 and R.sub.3 being other than hydrogen;

R.sub.4 is methyl, ethyl, n-propyl or trifluoromethyl;

R.sub.5 is hydrogen or lower alkyl;

R.sub.6 is carboxylic acid, or esters or prodrugs;

R.sub.7 is hydrogen or an alkanoyl or an aroyl.

In addition, a method is provided for preventing, inhibiting or treating

a disease associated with metabolism dysfunction or which is dependent upon the expression of a T.sub.3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T.sub.3 regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **280777-88-0P 378786-34-6P 378786-35-7P**
378786-36-8P 378786-37-9P 378786-38-0P
378786-39-1P 378786-40-4P 378786-41-5P
((aryloxy)benzamide ligands for thyroid receptor)
RN 280777-88-0 USPATFULL
CN Glycine, N-[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 378786-34-6 USPATFULL
CN Glycine, N-[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]-2-methylbenzoyl]- (9CI) (CA INDEX NAME)



RN 378786-35-7 USPATFULL
CN Glycine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]-2-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 378786-36-8 USPATFULL

CN Glycine, N-[3,5-dibromo-2-ethyl-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 378786-37-9 USPATFULL
CN Glycine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]-2-propylbenzoyl]- (9CI) (CA INDEX NAME)



RN 378786-38-0 USPATFULL
CN Glycine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]-2-methylbenzoyl]- (9CI) (CA INDEX NAME)



RN 378786-39-1 USPATFULL
CN Glycine, N-[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]-2-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 378786-40-4 USPATFULL

CN Glycine, N-[3,5-dichloro-2-ethyl-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 378786-41-5 USPATFULL
CN Glycine, N-[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]-2-propylbenzoyl]- (9CI) (CA INDEX NAME)



L11 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:904080 HCAPLUS
DOCUMENT NUMBER: 136:19947
TITLE: Benzamide ligands for the thyroid receptor
INVENTOR(S): Ryono, Denis E.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001094293	A2	20011213	WO 2001-US17742	20010601 <--
WO 2001094293	A3	20020606		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6395784	B1	20020528	US 2001-871347	20010531 <--
CA 2411062	AA	20011213	CA 2001-2411062	20010601 <--
AU 2001068132	A5	20011217	AU 2001-68132	20010601 <--
EP 1292568	A2	20030319	EP 2001-946036	20010601 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004524261 T2 20040812 JP 2002-501810 20010601 <--
PRIORITY APPLN. INFO.: US 2000-210102P P 20000607 <--
WO 2001-US17742 W 20010601 <--
OTHER SOURCE(S): MARPAT 136:19947

GI



I



II

AB Benzamides such as I were prepared for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene. Thus, I was prepared in 5 steps starting from 4'-hydroxy-2'-methylacetophenone and proceeding via II (R = Me, H).

IT **280777-88-0P 378786-34-6P 378786-35-7P**
378786-36-8P 378786-37-9P 378786-38-0P
378786-39-1P 378786-40-4P 378786-41-5P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
((aryloxy)benzamide ligands for thyroid receptor)

RN 280777-88-0 HCAPLUS
CN Glycine, N-[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 378786-34-6 HCAPLUS
CN Glycine, N-[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]-2-methylbenzoyl]- (9CI) (CA INDEX NAME)



RN 378786-35-7 HCAPLUS
CN Glycine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]-2-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 378786-36-8 HCAPLUS
CN Glycine, N-[3,5-dibromo-2-ethyl-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 378786-37-9 HCAPLUS
CN Glycine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]-2-propylbenzoyl]- (9CI) (CA INDEX NAME)



RN 378786-38-0 HCAPLUS
CN Glycine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]-2-methylbenzoyl]- (9CI) (CA INDEX NAME)



RN 378786-39-1 HCAPLUS
CN Glycine, N-[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]-2-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 378786-40-4 HCAPLUS
CN Glycine, N-[3,5-dichloro-2-ethyl-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 378786-41-5 HCAPLUS
CN Glycine, N-[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]-2-propylbenzoyl]- (9CI) (CA INDEX NAME)



L11 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:457018 HCAPLUS
DOCUMENT NUMBER: 133:89793
TITLE: Preparation of 4-(4-hydroxyphenoxy)phenylacetyl amino

acids and related compounds as novel thyroid receptor ligands

INVENTOR(S): Hangeland, Jon; Zhang, Minsheng; Caringal, Yolanda; Ryono, Denis; Li, Yi-lin; Malm, Johan; Liu, Ye; Garg, Neeraj; Litten, Chris; Garcia Collazo, Ana Maria; Koehler, Konrad

PATENT ASSIGNEE(S): Karo Bio AB, Swed.; et al.

SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000039077	A2	20000706	WO 1999-IB2084	19991223 <--
WO 2000039077	A3	20000921		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2356319	AA	20000706	CA 1999-2356319	19991223 <--
BR 9916851	A	20011016	BR 1999-16851	19991223 <--
EP 1144370	A2	20011017	EP 1999-962486	19991223 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
TR 200101834	T2	20011221	TR 2001-200101834	19991223 <--
JP 2002533432	T2	20021008	JP 2000-590990	19991223 <--
AU 758202	B2	20030320	AU 2000-18855	19991223 <--
NZ 512422	A	20040227	NZ 1999-512422	19991223 <--
NO 2001002931	A	20010821	NO 2001-2931	20010613 <--
ZA 2001004932	A	20030115	ZA 2001-4932	20010615 <--
US 6989402	B1	20060124	US 2001-868889	20010914 <--
US 2005282872	A1	20051222	US 2005-189654	20050726 <--

PRIORITY APPLN. INFO.:	GB 1998-28442	A	19981224 <--
	WO 1999-IB2084	W	19991223 <--
	US 2001-868889	A3	20010914 <--

OTHER SOURCE(S): MARPAT 133:89793

GI



I

AB Title compds. I [R1 = halo, trifluoromethyl, alkyl, cycloalkyl; R2, R3 = H, halo, alkyl, at least one of R2 and R3 being other than H; n = 0-4; R4 is an (un)substituted heteroarom. moiety linked to (CH2)n via a nitrogen or carbon atom; an amine, including those in which the amine is derived from an alpha amino acid of either L- or D-stereochem., an

acylsulfonamide, or a carboxylic acid amide, with the proviso that when n = 0, then R4 can only be a carboxylic acid amide or an acylsulfonamide; R5 is H or an acyl or other group capable of bioconversion to generate the free phenol structure] were prepared for use in the treatment of diseases associated with metabolism dysfunction or which are dependent on the expression of a T3 regulated gene (such as obesity, hypercholesterolemia, atherosclerosis, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer, glaucoma, cardiac arrhythmia, and congestive heart failure). Thus, coupling of 3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid with D-methionine Me ester hydrochloride followed by hydrolysis afforded N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]-D-methionine.

IT **280777-33-5P 280777-34-6P 280777-35-7P**
280777-36-8P 280777-37-9P 280777-38-0P
280777-39-1P 280777-40-4P 280777-42-6P
280777-43-7P 280777-44-8P 280777-45-9P
280777-46-0P 280777-47-1P 280777-48-2P
280777-50-6P 280777-51-7P 280777-52-8P
280777-53-9P 280777-54-0P 280777-55-1P
280777-56-2P 280777-57-3P 280777-58-4P
280777-88-0P 280779-25-1P 280779-31-9P
280779-32-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (hydroxyphenoxy)phenylacetyl amino acids and related compds. as novel thyroid receptor ligands)

RN 280777-33-5 HCAPLUS
CN D-Valine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-34-6 HCAPLUS
CN D-Leucine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-35-7 HCAPLUS
CN L-Cysteine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-S-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-36-8 HCAPLUS
CN D-Tyrosine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-37-9 HCAPLUS
CN L-Ornithine, N2-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 280777-38-0 HCAPLUS
CN Butanoic acid, 2-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-39-1 HCAPLUS
CN L-Valine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-40-4 HCAPLUS
CN L-Leucine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-42-6 HCAPLUS
CN L-Cysteine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-43-7 HCAPLUS
CN Glycine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-
(9CI) (CA INDEX NAME)



RN 280777-44-8 HCAPLUS
CN L-Lysine, N2-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-45-9 HCAPLUS
CN D-Lysine, N2-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-46-0 HCAPLUS
CN Alanine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-2-
methyl- (9CI) (CA INDEX NAME)



RN 280777-47-1 HCAPLUS
CN Benzeneacetic acid, α-[[3,5-dibromo-4-[4-hydroxy-3-(1-
methylethyl)phenoxy]benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-48-2 HCAPLUS
CN Benzeneacetic acid, α-[[3,5-dibromo-4-[4-hydroxy-3-(1-
methylethyl)phenoxy]benzoyl]amino]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-50-6 HCAPLUS
CN Phenylalanine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-α-methyl- (9CI) (CA INDEX NAME)



RN 280777-51-7 HCAPLUS
CN L-Isoleucine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-52-8 HCAPLUS
CN D-Methionine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-53-9 HCAPLUS
CN L-Methionine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-54-0 HCAPLUS
CN L-Phenylalanine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-55-1 HCAPLUS
CN D-Phenylalanine, N-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-56-2 HCAPLUS
CN Cyclohexanepropanoic acid, α-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-57-3 HCAPLUS
CN L-Lysine, N2-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-N6-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-58-4 HCAPLUS
CN D-Lysine, N2-[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-N6-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280777-88-0 HCAPLUS
CN Glycine, N-[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 280779-25-1 HCAPLUS
CN D-Methionine, N-[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280779-31-9 HCAPLUS
CN L-Serine, N-[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280779-32-0 HCAPLUS
CN D-Serine, N-[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Cl
O
H
N
R
HO
Cl
OH
CO_2H
O
i-Pr

THIS PAGE LEFT BLANK

```
=> d his ful

     (FILE 'HOME' ENTERED AT 14:12:53 ON 07 SEP 2006)

     FILE 'REGISTRY' ENTERED AT 14:13:00 ON 07 SEP 2006
L1             STR
L2           1 SEA SSS SAM L1
               D SCAN
L3          44 SEA SSS FUL L1
L4             STR L1
L5           0 SEA SSS SAM L4
L6           3 SEA SSS FUL L4
L7          44 SEA ABB=ON  L3 OR L6

     FILE 'HCAPLUS' ENTERED AT 14:17:42 ON 07 SEP 2006
L8           3 SEA ABB=ON  L7
L9           2 SEA ABB=ON  L8 AND (PRD<20020710 OR PD<20020710)

     FILE 'USPATFULL' ENTERED AT 14:18:31 ON 07 SEP 2006
L10          3 SEA ABB=ON  L8 AND (PRD<20020710 OR PD<20020710)

     FILE 'HCAPLUS, USPATFULL' ENTERED AT 14:18:43 ON 07 SEP 2006
L11          5 DUP REMOV L9 L10 (0 DUPLICATES REMOVED)

     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:    6 SEP 2006  HIGHEST RN 905963-91-9
     DICTIONARY FILE UPDATES:   6 SEP 2006  HIGHEST RN 905963-91-9

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/ONLINE/UG/regprops.html

     FILE HCAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     the American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
     of this information, without the prior written consent of CAS, is
     strictly prohibited.

     FILE COVERS 1907 - 7 Sep 2006  VOL 145 ISS 11
```

with iso-Pr – see d que stat

with Me – see d que stat

2 cits from CAplus

3 cits from USpatfull

THIS PAGE LEFT BLANK

FILE LAST UPDATED: 6 Sep 2006 (20060906/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 7 Sep 2006 (20060907/PD)
FILE LAST UPDATED: 7 Sep 2006 (20060907/ED)
HIGHEST GRANTED PATENT NUMBER: US7103915
HIGHEST APPLICATION PUBLICATION NUMBER: US2006200885
CA INDEXING IS CURRENT THROUGH 5 Sep 2006 (20060905/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 7 Sep 2006 (20060907/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2006

```
=> log hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    5.06     405.10

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    0.00      -1.50

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 14:27:40 ON 07 SEP 2006
```